

Please type a plus sign (+) inside this box → 

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

# UTILITY PATENT APPLICATION TRANSMITTAL

(Only for new nonapplications under 37C.F.R. §1.53(b))

**APPLICATION ELEMENTS**

See MPEP chapter 600 concerning utility patent application contents.

- |     |  |  |   |
|-----|--|--|---|
| 1.  | <input checked="" type="checkbox"/> *Fee Transmittal Form (e.g., PTO/SB/17)<br><i>(Submit an original, and a duplicate for fee processing)</i>                                   | 7.   | <input type="checkbox"/> CD-ROM or CD-R in duplicate, large table or computer Program (Appendix)  |
| 2.  | <input type="checkbox"/> Applicant claims small entity status<br>See 37 CFR 1.27   | 8.   | Nucleotide and/or Amino Acid Sequence Submission<br><i>(if applicable, all necessary)</i>   |
| 3.  | <input checked="" type="checkbox"/> Specification [Total Pages <span style="border: 1px solid black; padding: 2px;">212</span> ]   | a.   | <input type="checkbox"/> Computer Readable Copy (CRF)   |
|     | - Descriptive title of the Invention   | b.   | Specification Sequence Listing on:  |
|     | - Cross References to Related Applications   | i.   | <input type="checkbox"/> CD-ROM or CD-R (2 copies)  |
|     | - Statement Regarding Fed sponsored R&D  | ii.  | <input type="checkbox"/> Paper  |
|     | - Reference to sequence listing, a table, or a computer program listing appendix   | c.   | <input type="checkbox"/> Statement verifying identity of above copies   |
|     | - Background of the Invention  |  |   |
|     | - Brief Summary of the Invention   |  |   |
|     | - Brief Description of the Drawings ( <i>if filed</i> )  |  |   |
|     | - Detailed Description   |  |   |
|     | - Claim(s)   |  |   |
|     | - Abstract of the Disclosure   |  |   |
| 4.  | <input type="checkbox"/> Drawing(s) (35 U.S.C. 113) [Total sheets <span style="border: 1px solid black; padding: 2px;"> </span> ]  | 9.   | <input checked="" type="checkbox"/> Assignment Papers (cover sheet & document(s))   |
| 5.  | <input checked="" type="checkbox"/> Oath or Declaration [Total pages <span style="border: 1px solid black; padding: 2px;">4</span> ]   | 10.  | <input type="checkbox"/> 37 CFR 3.73(b) Statement <input checked="" type="checkbox"/> Power of Attorney<br><i>(when there is an assignee)</i> |
|     | a. <input type="checkbox"/> Newly executed (original or copy)  | 11.  | <input type="checkbox"/> English Translation Document ( <i>if applicable</i> )  |
|     | b. <input checked="" type="checkbox"/> Copy from a prior application (37 CFR §1.63(d))<br><i>(for continuation/divisional with Box 18 completed)</i>                             | 12.  | <input checked="" type="checkbox"/> Information Disclosure Statement (IDS)/PTO-1449 <input type="checkbox"/> Copies of IDS Citations          |
|     | i. <input type="checkbox"/> <b>DELETION OF INVENTOR(S)</b><br>Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).  | 13.  | <input checked="" type="checkbox"/> Preliminary Amendment   |
| 6.. | <input type="checkbox"/> Application Data Sheet. See 37 CFR 1.76   | 14.  | <input checked="" type="checkbox"/> Return Receipt Postcard (MPEP 503)<br><i>(Should be specifically itemized)</i>                            |
| 18. | If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37CFR 1.76. |  |   |
|     | <input type="checkbox"/> Continuation  | <input checked="" type="checkbox"/> Divisional | <input type="checkbox"/> Continuation-in-part (CIP)      of prior application No: <u>09/764,306</u>   |


Prior application information: Examiner Kahsay Habte Group/Art Unit: 1624

For CONTINUATION OR DIVISIONAL APPS only. The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts

**18. CORRESPONDENCE ADDRESS**

Customer Number or Bar Code Label *(Insert Customer No. or Attach bar code label here)* or  Correspondence address below

28940

Name			
Address			
City	State	Zip Code	
Country	Telephone	Fax	
NAME (Print/type)	Joseph F. Reidy	Registration No. (Attorney/Agent)	39,340
Signature			Date
			July 17, 2003

 10/6/2003  
 07/17/03

**FEE TRANSMITTAL**  
**for FY 2003**

Applicant claims small status. See 37 CFR 1.27

Total Amount of Payment (\$918.00)

Complete if Known

Application Number	To be assigned
Filing Date	Herewith
First Named Inventor	Steven Lee Bender
Examiner Name	Kahsay Habte
Art Unit	1624
Attorney Docket No.	AG0073-01-US

METHOD OF PAYMENT (check all that apply)

Check  Credit Card  Money Order  Other  None  
 Deposit Account:

Deposit Account Number **500329**

Deposit Account Name **Agouron Pharmaceuticals, Inc.**

The Commissioner is authorized to: (check all that apply)

Charge fee(s) indicated below  Credit any overpayments  
 Charge any additional fee(s) during the pendency of this application  
 Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.

FEE CALCULATION (continued)


**3. ADDITIONAL FEES**

Large Entity		Small Entity		Fee Description	Fee Paid
Fee Code	Fee (\$)	Fee Code	Fee (\$)		
1051	130	2051	65	Surcharge - late fee or oath	
1052	50	2052	25	Surcharge - late filing fee or cover sheet	
1053	130	1053	130	Non-English specification	
1812	2,520	1812	2,520	For filing a request for reexamination	
1804	920*	1804	920*	Requesting publication of SIR prior to Examiner action	
1805	1,840*	1805	1,840*	Requesting publication of SIR after Examiner action	
1251	110	2251	55	Extension for reply within first month	
1252	410	2252	205	Extension for reply within second month	
1253	930	2253	465	Extension for reply within third month	
1254	1,450	2254	725	Extension for reply within fourth month	
1255	1,970	2255	985	Extension for reply within fifth month	
1401	320	2401	160	Notice of Appeal	
1402	320	2402	160	Filing a brief in support of an appeal	
1403	280	2403	140	Request for oral hearing	
1451	1,510	1451	1,510	Petition to institute a public use proceeding	
1452	110	2452	55	Petition to revive - unavoidable	
1453	1,300	2453	650	Petition to revive - unintentional	
1501	1,300	2501	650	Utility issue fee (or reissue)	
1502	470	2502	235	Design issue fee	
1503	630	2503	315	Plant issue fee	
1460	130	1460	130	Petitions to the Commissioner	
1807	50	1807	50	Processing fee under 37 CFR 1.17 (q)	
1801	750	2801	375	Request for Continued Examination (RCE)	
1806	180	1806	180	Submission of Information Disclosure Statement	
8021	40	8021	40	Recording each patent assignment per property (times number of properties)	
1809	750	2809	375	Filing a submission after final rejection (37 CFR 1.129(a))	
1810	750	2810	375	For each additional invention to be examined (37 CFR 1.129(b))	

\*Reduced by Basic Filing Fee Paid

SUBTOTAL (3) (\$)

0

SUBMITTED BY		Complete (if Applicable)	
Name (Printed/Type)	Joseph F. Reidy	Reg. Number	39,340
Signature		Date	July 17, 2003
		Telephone	858-622-7320

AG0073-01-US

Transmittal Letter for Divisional Application

certificate of Mailing (37 C.F.R. §1.10);

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail (EV341079272US in an envelope addressed to:

Mail Stop: Patent Application Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450 on this 17th day of July 2003.

s/ Danielle Dixon  
Danielle Dixon

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

**In re the Application of:**  
Steven Lee Bender et al.

**Group Art Unit: 1624**

**Serial No.: Not Yet Assigned**

**Examiner: HABTE, KAHSAY**

**Filed: Herewith**

**For: AMIDE COMPOUNDS AND  
PHARMACEUTICAL COMPOSITIONS FOR  
INHIBITING PROTEIN KINASES, AND  
METHODS FOR THEIR USE**

Mail Stop: Patent Applications  
Honorable Commissioner for Patents  
Alexandria, VA 22313-1450


**TRANSMITTAL LETTER**

Sir:

Submitted herewith are the following documents:

Utility Patent Application Transmittal	1 page;
Fee Transmittal	1 page + Duplicate;
Preliminary Amendment	23 pages;
Information Disclosure Statement	2 pages;
PTO Form SB.08B (1449)	11 pages;
Combined Declaration and Power of Attorney	4 pages;
Assignment and Cover Sheet	5 pages;
Specification	212 pages Total;
• Claims	15 pages; and
• Abstract	1 page.

Respectfully Submitted,

  
Joseph F. Reidy  
Attorney for Applicants  
Reg. No. 39,340

Date: 7/17/2003

Agouron Pharmaceuticals, Inc./A Pfizer Company  
Patent Department  
10777 Science Center Drive  
San Diego, California 92121  
Phone: (858) 622-7320  
Fax: (858) 678-8233